News

An already approved drug could help eliminate resistance to the most effective treatment against metastatic breast cancer.

Cognitive reserve – the term given to the capacity to maximise cognitive performance through differential engagement of cerebral networks or alternative cognitive strategies – protects the cognitive functions of brain tumour patients.

A promising target has been identified in cancer cells that could be used in combination with standard care to prevent acquired treatment resistance in metastatic breast cancer.

Researchers have found a possible explanation as to why the risk of breast cancer is increased by higher breast density and older age.

A team of immune-engineers have developed a novel biomaterials-based immunotherapy approach named SIVET that has the potential to break down barriers.

Researchers have developed the first therapy of its kind that disrupts prostate cancer cells’ metabolism and releases the chemotherapy medication cisplatin into the weakened cells, causing them to die.

Researchers have identified mutations that predispose patients to a rare hereditary syndrome that increases kidney cancer risk, which could be a drug target for the condition.

Researchers have identified a promising target that may assist in the development of new solutions for tumor resistance to targeted cancer therapies.

Results from a new Phase 2 clinical trial show that a combination of targeted drugs led to a median 91% shrinkage of a rare type of brain tumor – papillary craniopharyngioma (PCP) – in a small study of 16 participants.

A new study explains how basic cellular structures common to most life forms collaborate to fuel growth in a model plant organism. The findings could shed light on corresponding mechanisms in human cells.